Buy ASMB Ahead of Potential HPI Opt-In and HDV Program Readout
Assembly Biosciences (ASMB) is a small-cap antiviral developer with a tight float, deep Gilead collaboration, and binary development catalysts ahead. We view a calibrated long position as favorable given the company’s optionality on helicase-primase inhibitor (HPI) programs and nascent HDV candidate work, balanced against negative cash flow and val…